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Background: The transcription factor E2F4 controls proliferation of normal and cancerous intestinal epithelial cells.
E2F4 localization in normal human intestinal epithelial cells (HIEC) is cell cycle-dependent, being cytoplasmic in
quiescent differentiated cells but nuclear in proliferative cells. However, the intracellular signaling mechanisms
regulating such E2F4 localization remain unknown.
Results: Treatment of quiescent HIEC with serum induced ERK1/2 activation, E2F4 phosphorylation, E2F4 nuclear
translocation and G1/S phase transition while inhibition of MEK/ERK signaling by U0126 prevented these events.
Stimulation of HIEC with epidermal growth factor (EGF) also led to the activation of ERK1/2 but, in contrast to
serum or lysophosphatidic acid (LPA), EGF failed to induce E2F4 phosphorylation, E2F4 nuclear translocation and
G1/S phase transition. Furthermore, Akt and GSK3β phosphorylation levels were markedly enhanced in serum- or
LPA-stimulated HIEC but not by EGF. Importantly, E2F4 phosphorylation, E2F4 nuclear translocation and G1/S phase
transition were all observed in response to EGF when GSK3 activity was concomitantly inhibited by SB216763.
Finally, E2F4 was found to be overexpressed, phosphorylated and nuclear localized in epithelial cells from human
colorectal adenomas exhibiting mutations in APC and KRAS or BRAF genes, known to deregulate GSK3/β-catenin
and MEK/ERK signaling, respectively.
Conclusions: The present results indicate that MEK/ERK activation and GSK3 inhibition are both required for E2F4
phosphorylation as well as its nuclear translocation and S phase entry in HIEC. This finding suggests that
dysregulated E2F4 nuclear localization may be an instigating event leading to hyperproliferation and hence, of
tumor initiation and promotion in the colon and rectum.
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E2F transcription factors control exit from cell quies-
cence and progression through G1 and S phase entry
[1,2]. In mammalian cells, E2F consists of a family of
related proteins that includes eight members which pair
with a heterodimeric partner (DP1 or DP2) [2]. The first
three family members, E2F1, 2 and 3a, are primarily
considered as transcriptional activators. Their functions* Correspondence: nathalie.rivard@usherbrooke.ca
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reproduction in any medium, provided the orare partially redundant and simultaneous abrogation of
the three is lethal at an early embryonic stage [3]. Unlike
E2F1, 2 or 3a, E2F4 and 5 have mostly been described
as transcriptional repressors, at least in fibroblasts [2].
However, in rapidly renewing tissues such as bone mar-
row, skin and digestive tract where E2F4 is predo-
minantly expressed [4], this latter E2F family member
appears to act as an activator of both transcription and
cell cycle progression. Indeed, in mice, deletion of the
E2F4 gene causes a reduction in the number of eryth-
rocytes due to impaired proliferation of progenitors in
bone marrow [5]. In skin, overexpression of E2F4 resultsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hyperplasia [6]. In the small intestine, loss of E2F4 results
in a significant decline in proliferative zones (crypts)
and a shortening of intestinal villi [4]. In contrast, loss
of E2F1 expression does not affect intestinal development
or homeostasis [7]. In addition, E2F4 is also strongly
and preferentially expressed in proliferative zones of
embryonic mouse intestine [8] and human fetal intestinal
epithelium [9]. Finally and more importantly, inhibition
of E2F4 expression by RNA interference in normal and
cancerous intestinal epithelial cells reveals that E2F4 is
necessary for S-phase entry and proliferation [10].
Several reports indicate that subcellular localization
of E2F4 controls its transcriptional activity [11-14]. Ac-
cordingly, we have recently shown that the cellular
localization of E2F4 is cell cycle-dependent in normal
intestinal epithelial cells. Indeed, in contrast to E2F1,
which constitutively resides in the nucleus throughout
the cell cycle, E2F4 is mostly distributed in the cytoplasm
of quiescent intestinal crypt cells and translocates into
the nucleus upon serum stimulation [9]. Hence, this
suggests that cytoplasmic sequestration or nuclear export
of E2F4 may provide a means to control its transcriptional
activity. However, the intracellular mechanisms by which
serum growth factors induce E2F4 nuclear transloca-
tion remain to be identified.
Herein, we show that activation of MEK/ERK signaling
by serum is required for E2F4 nuclear translocation as
well as for G1/S phase transition of human non immor-
talized intestinal epithelial crypt cells (HIEC) in culture.
Our results demonstrate that ERK1/2 directly and rap-
idly phosphorylates E2F4 following serum stimulation
and is correlated with its increased transcriptional ac-
tivity and S phase entry. However, although epidermal
growth factor (EGF) treatment resulted in rapid activa-
tion of ERK1/2, it was not sufficient to promote E2F4
translocation into the nucleus or G1/S phase transition
in HIEC. Additional GSK3 inhibition was required for
these events to occur in presence of EGF. Finally, we
show that E2F4 is overexpressed, phosphorylated and
localized in the nucleus of epithelial cells from colorectal
adenomas exhibiting APC and KRAS or BRAF mutations.
Taken together, our results emphasize the importance
of regulating E2F4 localization for proliferation in nor-
mal human intestinal epithelial cells as well as in intes-
tinal tumors.
Results
MEK/ERK pathway is required for E2F4 nuclear
translocation and G1/S phase transition of HIEC
We have previously shown that E2F4 is required for
proper expression of many cell cycle regulatory proteins
controlling G1/S phase transition and for proliferation
of normal human intestinal epithelial cells (HIEC) [10].In contrast to E2F1, which is constitutively localized in
the nucleus, E2F4 has a diffuse cytoplasmic localization
in quiescent HIEC and a nuclear localization in prolifer-
ative cells suggesting that its localization is regulated by
signaling pathways activated by mitogens [9]. In light of
the above, we analyzed the signaling pathways that could
be involved in serum-induced E2F4 nuclear transloca-
tion and G1/S phase transition in HIEC. We first verified
the involvement of the MEK/ERK pathway given that
we had previously demonstrated that sustained activation
of ERK1/2 is required for intestinal epithelial cells to enter
S-phase [15]. Among physiological events relevant for G1/
S phase transition, there is the phosphorylation of the
retinoblastoma gene product pRb by cyclin D/Cdk4,6
and cyclin E/Cdk2 complexes, which causes the release
and activation of E2F/DP transcription factors [1]. E2F4
localization and hyperphosphorylation of pRb were there-
fore analyzed following treatment of HIEC with serum
in absence or presence of U0126, a potent inhibitor of
MEK1/2 (the upstream activators of ERK1/2). As expected,
addition of 20 μM U0126 to HIEC potently inhibited
serum-induced ERK1/2 phosphorylation (Figure 1A)
without affecting phosphorylation of other signaling kinases
such as ERK5 and AKT (Additional file 1: Figure S1). Of
note, the stimulatory effect of serum on cyclin D1 expres-
sion, p27 down-regulation and pRb hyperphosphorylation
was also abolished by U0126. Furthermore, U0126 treat-
ment totally prevented nuclear translocation of E2F4 in
response to serum (Figure 1B).
E2F4 is phosphorylated by ERK upon serum stimulation
Western blot analysis of E2F4 revealed that 30 min
serum stimulation with or without U0126 did not affect
the total expression levels of E2F4 (Figure 2A, upper
first panel), even after 24 h stimulation (data not shown).
However, when using higher-resolution gels, three major
bands of approximately 60–63 kDa were detected in
serum-deprived HIEC, whereas only one band with a
lower electrophoretic mobility was observed in serum-
stimulated cells after 30 min (Figure 2A, arrows). Of
note, treatment with U0126 abolished ERK phosphoryl-
ation and markedly reduced the expression of this latter
prominent band (Figure 2A). Similar results were ob-
tained when we used the more specific and potent MEK
inhibitor PD184352 (Additional file 2: Figure S2). We
therefore investigated whether E2F4 phosphorylation could
be responsible for this occurrence. E2F4 was immuno-
precipitated from serum-deprived or serum-stimulated
HIEC. Beads containing E2F4 immune complexes were
then incubated with the serine/threonine phosphatase PP1
in order to dephosphorylate serine/threonine residues
on E2F4. As shown in Figure 2B, immunoprecipitated
E2F4 exhibited three bands in control HIEC, in con-
trast to one prominent band in serum-stimulated cells.
Figure 1 MEK/ERK pathway is required for E2F4 nuclear translocation and G1/S phase transition in HIEC. A. Subconfluent HIEC were
serum-deprived for 36 h, treated or not (DMSO) during 10 min with 20 μM U0126 and then stimulated during 30 min or 24 h with 5% FBS. Thereafter,
cells were lysed and proteins were analyzed by SDS-PAGE for Western blot analysis of the expression of ERK2, pRb, cyclin D1, p27, phosphorylated
ERK1/2 and β-actin. B. HIEC grown on coverslips were serum-deprived during 36 h and then stimulated with 5% FBS with or without 20 μM U0126
(or DMSO). After 24 h, cells were fixed using 3% paraformaldehyde, permeabilized and analyzed by immunofluorescence for E2F4 expression.
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serum-stimulated cells with the PP1 phosphatase modified
the electrophoretic profile of E2F4, reducing the amount
of the slower migrating form of E2F4. Moreover, the use
of antibodies recognizing phosphorylated serine revealed
that E2F4 was phosphorylated on serine residue(s) upon
serum stimulation (Figure 2C). Of note, the levels of phos-
phorylated serine residues in immunoprecipitated E2F4
were not completely reduced by U0126 treatment,
suggesting that E2F4 could also be phosphorylated in
absence of serum and ERK activation in quiescent HIEC
as we previously observed [9]. Kinase assays with active
recombinant ERK1 confirmed that ERK1 strongly phos-
phorylated immunoprecipitated HA-tagged E2F4 in vitro
(Figure 2D). These results clearly indicate that E2F4 is
phosphorylated on serine residue(s) in response to serum
in a MEK-dependent manner. The data also suggest
ERK1/2 as candidate kinases.
Phosphorylation of E2F4 on serines 244 and 384
promotes its transcriptional activity
We identified seven putative ERK phosphorylation sites
followed by a proline residue in E2F4 human sequence:
T14, S202, S218, T224, S244, T248 and S384. Each ofthese specific serine/threonine residues was mutated in-
to alanine. As shown in Figure 3A, mutation of serines
244 and 384 resulted in modification of the E2F4 elec-
trophoretic profile in 293T cells, decreasing the amount
of the slower migrating forms of E2F4. Of note, these
slower migrating forms almost completely disappeared
when both serines were mutated into alanine (Figure 3B).
Accordingly, the S244A, S384A and the S244A/S384A
mutants were much less phosphorylated by recombinant
ERK1 in in vitro kinase assays (Figure 3C). Finally, the
effect of E2F4 phosphorylation on E2F4 site-dependent
transcription was measured on the thymidine kinase
promoter, which represents the physiological E2F target
gene [1,2]. Mutation of each of these serines into
phosphomimetic sites, namely S244E, S384E and S244E/
S384E, significantly increased the transcriptional activity
of E2F4 (Figure 3D), confirming the involvement of the
phosphorylation of these residues in the control of E2F4
transcriptional activity. To verify if mutations of serines
244 and 384 also alter the localization of E2F4, the
S244A, S384A and the S244A/S384A E2F4 mutants
were transiently expressed in HIEC and analyzed for
their subcellular localization. As shown in Figure 3E,
when overexpressed, wild-type E2F4 was mainly found
Figure 2 E2F4 is phosphorylated by ERK kinases. A. Subconfluent HIEC were serum-deprived for 36 h, treated or not (DMSO) during 10 min
with 20 μM U0126 and then stimulated during 30 min with 5% FBS. Thereafter, cells were lysed and proteins were analyzed by SDS-PAGE (on
7.5% or 12% acrylamide gels) for Western blot analysis of the expression of phosphorylated ERK1/2, total ERK1/2, E2F4 and β-actin. B. E2F4 was
immunoprecipitated from subconfluent serum-deprived and 30 min serum-stimulated HIEC. Beads containing E2F4 immune complexes were
incubated with PP1 phosphatase for 30 min prior to Western blot analysis for E2F4 expression. C. E2F4 was immunoprecipitated from HIEC
stimulated during 30 min with FBS in presence or absence of 20 μM U0126. E2F4 immune complexes were analyzed by SDS-PAGE for Western
blot analysis with antibodies recognizing phosphorylated serine or E2F4. D. 293T cells were transfected with pCDNA3.1 containing or not HA-
E2F4. After 48 h, cells were lysed and immunoprecipitated with anti-HA antibody. Kinase assays were performed by incubating beads containing
HA-E2F4 immune complexes with active recombinant ERK1 for 5 min. Radiolabeled proteins were separated on SDS-PAGE and autoradiographed
or analyzed by Western blot for the expression of E2F4.
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nucleus. By contrast, all the phosphomimetic mutants
were consistently less expressed into the cytoplasm and
more detected into the nucleus, correlating with their
increased transcriptional activity (Figure 3D). Neverthe-
less, the observation of some cytoplasmic staining for the
phospho-mimetic mutants indicate that other mechanisms
than phosphorylation might also be involved in the
control E2F4 nuclear translocation.
EGF neither induces E2F4 phosphorylation and nuclear
translocation nor G1/S phase transition in HIEC
To better understand the mechanisms controlling sub-
cellular E2F4 localization during G1/S phase transition
in HIEC, we analyzed the impact of growth factors such
as EGF and lysophosphatidic acid (LPA) on these events.
EGF is a classical growth factor that can activate many
intracellular signaling cascades including the ERK1/2
MAP Kinase cascade [16,17]. In addition, we and others
have previously demonstrated that EGF induces proli-feration of rat immortalized intestinal epithelial cells in
a MEK-dependent manner [17,18]. In the present series
involving human intestinal epithelial cells, although EGF
treatment resulted in a rapid and sustained activation
of ERK1/2 (at least > 4 h) and in a modest induction of
cyclin D1, it was not sufficient to mimic serum-induced
cyclin A expression, p27 down-regulation and pRb hy-
perphosphorylation (Figure 4A). Importantly, in con-
trast to serum, EGF stimulation did not trigger E2F4
translocation into the nucleus and no Ki67 staining was
observed (Figure 4B). Of note, Western blot analysis
with an anti-E2F4 antibody revealed three major bands
in EGF-stimulated HIEC similar to controls, whereas
E2F4 displayed a typical phosphorylated low electro-
phoretic mobility in serum-stimulated cells (Figure 4C).
Neither pRb hyperphosphorylation nor Ki67 staining
was observed in the presence of lower and higher EGF
concentrations ranging from 2 ng/ml to 1 ug/ml (data not
shown), thus eliminating the likelihood of overactivation
or underactivation of EGF receptors. Furthermore, HIEC
Figure 3 Phosphorylation of E2F4 on serines 244 and 384 promotes its transcriptional activity. A. and B. 293T cells were transfected with
pCDNA3.1 empty vector (EV) or encoded for HA-tagged- human wild-type (WT) E2F4 or E2F4 mutants as indicated. After 48 h, cell lysates
were analyzed for the expression of E2F4 proteins. C. 293T cells were transfected with EV or encoding for HA-E2F4 WT, HA-E2F4 S244A, HA-
E2F4 S384A or HA-E2F4 S244A/S384A. After 48 h, cells were lysed and immunoprecipitated with anti-HA antibody. Kinase assays were
performed by incubating beads containing HA-E2F4 immune complexes with recombinant ERK1 for 5 min. Radiolabeled proteins were
separated on SDS-PAGE and autoradiographed or analyzed for the expression of E2F4. D. 293T cells were co-transfected with DP2, thymidine
kinase luciferase reporter with either empty vector, HA-wtE2F4, HA-E2F4 S244E, HA-E2F4 S384E or HA-E2F4 S244/S384E. pRL-SV40 Renilla
luciferase reporter control vector was also co-transfected. Forty-eight hours following transfection, luciferase activity was quantified and
normalized using the Renilla reporter, with the empty vector condition set at 1. A representative experiment of three experiments is shown.
*Significantly different from control at p < 0.001, **Significantly different from WT at p < 0.002, ***Significantly different from WT at p < 0.001
(Student’s t test). E. HIEC grown on coverslips were transfected with either empty vector, HA-wtE2F4, HA-E2F4 S244E, HA-E2F4 S384E or
HA-E2F4 S244/S384E. After 48 h, cells were analyzed by immunofluorescence for subcellular localization of HA-tagged E2F4 forms. Total cell
number was determined using DAPI staining and cells exhibiting E2F4 forms into the nucleus or into the cytoplasm or in both compartments
were counted. The percentage of cells exhibiting HA staining into the nucleus, into the cytoplasm or in both compartments was calculated
and shown in the graph. Representative experiment is shown.
Paquin et al. BMC Cell Biology 2013, 14:33 Page 5 of 14
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of incubation with EGF (data not shown). Hence, these
results indicate that EGF by itself is not able to trigger
S phase entry and proliferation of normal human non
immortalized intestinal epithelial crypt cells.
We next investigated the impact of LPA, a biologic-
ally active lysophospholipid that mediates a plethora
of cellular effects, including cell proliferation of many
cell types such as fibroblasts, breast cancer cells, me-
sangial cells, vascular smooth muscle cells, neuronal
cells and human colorectal cancer cells [19]. As shown
in Figure 4A and B, similarly to serum stimulation,LPA clearly induced ERK1/2 phos-phorylation and
HIEC cell cycle entry as visualized by pRb hyperphos-
phorylation, cyclin D1 expression, cyclin A expression,
decreased p27 expression, E2F4 nuclear translocation
and Ki67 staining. Western blot analysis with anti-
E2F4 antibody also indicated that LPA induced E2F4
phosphorylation to a level comparable to that observed
with serum (Figure 4D). Thus, in contrast to EGF, LPA
is sufficient to promote phosphorylation and nuclear
translocation of E2F4 as well as S-phase entry demon-
strating that LPA is an important contributing serum
growth factor for HIEC.
Figure 4 EGF neither induces E2F4 phosphorylation and nuclear translocation nor G1/S phase transition in HIEC. A. Subconfluent HIEC
were serum-deprived during 36 h, stimulated with 5% FBS or 100 ng/ml EGF or 10 μM LPA for 30 min, 4 h or 24 h. Equal amounts of whole cell
lysates were separated by SDS-PAGE, and proteins were analyzed by Western blotting with specific antibodies against phosphorylated ERK1/2,
pRb, cyclin D1, cyclin A, p27 and β-actin. B. Cells were also fixed after 24 h stimulation with 3% paraformaldehyde in PBS and permeabilized with
0.1% Triton X-100 for subsequent immunofluorescence staining of E2F4 and Ki67. Cells with nuclear E2F4 and Ki67 were counted in 10 fields.
Total cell number was determined using DAPI staining. Ratio of nuclear E2F4 expressing cells and Ki67 positive cells before/after serum, EGF or
LPA stimulation are shown. Of note, each cell exhibiting nuclear E2F4 was positive for Ki67 staining. Results are the mean ± SEM of an experiment
representative of 3. * Significant at p < 0.0001 compared to control cells (no serum) (Student’s t test). C and D. HIEC were serum-deprived during
36 h, stimulated with 5% FBS or 100 ng/ml EGF or 10 μM LPA for 30 min. Cell lysates were separated by 7.5% SDS-PAGE and proteins were
analyzed by Western blotting with specific antibodies against E2F4 and β-actin.
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translocation of E2F4 as well as G1/S phase transition
in HIEC
In order to elucidate why EGF, in contrast to LPA and
serum, failed to induce G1/S phase transition in HIEC, we
analyzed the phosphorylation levels of GSK3β. GSK3β is a
constitutively active serine/threonine kinase featured in
two signaling pathways that are of particular importance
for intestinal epithelial cell proliferation and colorectal
cancer: the Wnt/β-catenin pathway and the phospha-
tidylinositol 3-kinase (PI3K)/Akt pathway [16,20,21].
Indeed, Akt phosphorylates GSK3β on serine 9, leading
to inhibition of its constitutive kinase activity. GSK3β is
also a component of Wnt signaling, which is thought to
block GSK3-mediated β-catenin phosphorylation, lead-
ing to the accumulation and nuclear translocation of β-
catenin [22]. As shown in Figure 5A, serum markedly
induced phosphorylation levels of Akt and GSK3β after
both 30 min and 24 h stimulation. By contrast, stimula-
tion of HIEC with EGF only transiently increased
phosphorylation of Akt and GSK3β. Interestingly, LPAinduced a more sustained Akt and GSK3β phosphorylation
(Figure 5A).
These results prompted us to verify whether GSK3
inhibition was necessary for E2F4 phosphorylation and
nuclear translocation as well as G1/S phase transition
in HIEC. To test this hypothesis, a specific GSK3 in-
hibitor (SB216763) was used. HIEC were serum-starved
for 36 h, pre-treated 10 min with SB216763 and then
stimulated for 30 min or 24 h with EGF. As shown in
Figure 5B, a 24 h-treatment of HIEC with EGF or GSK3
inhibitor alone was not sufficient to significantly induce
expression of cyclin D1, p27 down-regulation or pRb
hyperphosphorylation in contrast to serum. However,
significant pRb hyperphosphorylation as well as cyclin D1
expression and p27 down-regulation were observed in
presence of EGF and SB216763. Furthermore, inhibition
of GSK3 significantly reduced phosphorylation of glycogen
synthase (GS) but enhanced the capacity of EGF to pro-
mote E2F4 phosphorylation (Figure 5C). Accordingly, in
presence of SB216763, EGF significantly induced E2F4
nuclear translocation and Ki67 staining (Figure 5D).
Figure 5 GSK3 inhibition is required for phosphorylation and nuclear translocation of E2F4 as well as G1/S phase entry of HIEC. A.
Subconfluent HIEC were serum-deprived during 36 h and then stimulated with 5% FBS or 100 ng/ml EGF or 10 μM LPA for 30 min and 24 h.
Equal amounts of whole cell lysates were analyzed by Western blotting with specific antibodies against phosphorylated Akt, phosphorylated
GSK3β and β-actin. B. Subconfluent HIEC were serum-deprived during for 36 h, stimulated with 5% FBS or 100 ng/ml EGF in presence or absence
of 20 μM SB216763 (or DMSO) for 24 h. Equal amounts of whole cell lysates were separated by SDS-PAGE, and proteins were analyzed by
Western blotting with specific antibodies against pRb, cyclin D1, p27 and β-actin. C. HIEC were serum-deprived during 36 h and then stimulated
with 5% FBS or 100 ng/ml EGF for 30 min with or without prior 10-min 20 μM SB216763 (or DMSO) treatment. Cell lysates were analyzed by
Western blotting with specific antibodies against E2F4, ERK2, phosphorylated ERK1/2, phosphorylated glycogen synthase (GS) and β-actin. D. Cells
were also fixed after 24 h stimulation and permeabilized with 0.1% Triton X-100 for subsequent immunofluorescence staining of E2F4 and Ki67.
Cells with nuclear E2F4 and positive for Ki67 staining were counted in 10 fields. Total cell number was determined using DAPI staining. Ratio of
nuclear E2F4 expressing cells and Ki67 positive cells before/after serum or EGF +/− SB216763 (SB) stimulations are shown. Of note, each cell
exhibiting nuclear E2F4 was positive for Ki67 staining. Results are the mean ± SEM of 2 separate experiments. * Significant at p < 0.05. **
Significant at p < 0.01. *** Significant at p < 0.005 compared to control cells (no serum) (Student’s t test).
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localized in human colorectal adenomas
Both MEK/ERK and GSK3 signaling pathways are thought
to be affected in early stages of colorectal cancer for-
mation due to frequent mutations in KRAS/BRAF and
APC genes respectively [23]. We therefore verified the
protein status of E2F4 in human colorectal adenomas.As shown in Figure 6A and B, adenomas displayed sig-
nificantly higher expression levels of E2F4 in compari-
son to their corresponding benign epithelium (margin).
More importantly, all normal specimens analyzed (resec-
tion margins, M) presented hypophosphorylated forms
of E2F4 (arrowhead) whereas all adenoma samples (A)
exhibited hyperphosphorylated forms of E2F4 (arrows)
Figure 6 E2F4 is overexpressed, phosphorylated and nuclear localized in epithelial cells of human colorectal adenomas. A. E2F4 and
β-actin protein levels were determined in six paired specimens of advanced adenomas by Western blot (resection margins (M) and primary
tumors). B. E2F4 expression levels were normalized to β-actin levels. E2F4 expression levels were also normalized to a mean of E2F4 expression
levels in every resection margins, resulting in a fold induction value. E2F4 protein contents in adenoma tissues relative to their corresponding
normal samples were analyzed by paired t-test. **, Significant at p < 0.01. C. Representative immunohistochemistry of E2F4 from frozen tissue
sections of resection margin and corresponding adenoma. Bars: 100 μm. Higher magnifications are shown on the left panels.
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demonstrated that E2F4 protein was especially overex-
pressed in the nucleus of all epithelial cells in colorectal
adenomas (Figure 6C, lower panels, arrows) while only
localized in the nucleus of certain cells along the colonic
crypt, presumably in proliferative cells (Figure 6C, rightpanel, arrows) as previously demonstrated [9]. Of note, all
of the adenomas analyzed exhibited APC inactivating mu-
tations (exon 15) in combination with KRAS (G12D, G13D,
Q61H) or BRAF (V600E) activating mutations. Hence, these
results emphasize the close correlation between the phos-
phorylation of E2F4 and its nuclear localization.
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The intestinal epithelium is the most vigorously self-
renewing tissue in adult mammals. Perturbations of nor-
mal tissue homeostasis attributable to genetic lesions or
environmental insults can lead to hyperproliferative dis-
eases of the intestinal tract such as cancer [24]. Intestinal
epithelial cell regulation has been studied extensively and
has revealed canonical Wnt/β-catenin, KRAS/MAPK and
PI3K/Akt signaling pathways as key regulators of cell
division and differentiation [16,18,20]. Normal cell division
is a tightly controlled process that only allows cells to
divide in a timely and restricted manner. As such, E2F
transcription factors control cell division by activating
the transcription of numerous genes involved in G1
and S phases [1,2]. Many previous analyses of E2F proteins
in intact intestinal epithelium or in cultured crypt cells
have demonstrated that nuclear E2F4 may be determinant
in the control of proliferation. Indeed, in mice, deletion
of E2F4 gene resulted in a significant decline in prolifera-
tive zones (crypts) and a shortening of intestinal villi [4].
Accordingly, double staining experiments in intact human
intestine revealed that crypt epithelial cells expressing high
levels of nuclear E2F4, were all positive for Ki67 and cyclin
A [9,10]. In this respect, decreased expression of E2F4
by RNA interference reduced the proliferation rate of
normal intestinal epithelial crypt cells and colorectal
cancer cells in culture [10]. Interestingly, in contrast to
E2F1, which resides constitutively in the nucleus through-
out the cell cycle, E2F4 protein is mostly distributed in
the cytoplasm of quiescent cells and translocates into the
nucleus upon serum stimulation [9]. Taken together, these
results suggest that the nuclear translocation of E2F4 may
represent a critical step in promoting G1/S transition in
intestinal epithelial crypt cells.
In the present study, we show that activation of the
MEK/ERK pathway by serum is required for E2F4 nu-
clear translocation as well as for G1/S phase transition
of human intestinal epithelial crypt cells. Accordingly,
several studies on cultured intestinal epithelial cells and
many other cell types have revealed a close correlation
between ERK activation and DNA synthesis while phar-
macological or molecular inhibition of ERK activity has
been shown to block cell cycle progression [15,25]. Not-
ably, like E2F4 [9], phosphorylated and activated forms
of ERK1/2 have been mostly detected in the nucleus of
undifferentiated proliferative crypt cells in human fetal
small intestine [18], hence supporting the role of these
kinases in cell cycle control of intestinal crypt cells.
Therefore, our results indicate that one of the mecha-
nisms by which ERK1/2 MAP Kinases induce intestinal
epithelial proliferation may be by promoting E2F4 nu-
clear translocation. Once into the nucleus, E2F4 may
control the expression of proteins necessary for entry
into S phase including cdc6, dihydrofolate reductase(dhfr), thymidine kinase, cyclin E, cyclin A, mcm3 and
DNA polymerase α as we have previously shown [2,10].
The exact molecular mechanism by which ERK1/2
promotes E2F4 nuclear translocation however remains
unclear. Herein, E2F4 was found to be rapidly phos-
phorylated on serine residue(s) in serum-treated cells
and that this phosphorylation was MEK-dependent. Of
importance, we observed a strong correlation between
the rapid phosphorylation of E2F4 and its subsequent
nuclear translocation. Hence, one could speculate that
phosphorylation of E2F4 by ERK1/2 is necessary to induce
its translocation into the nucleus. However, although
E2F4 phosphorylation was observed within 30 minutes
after serum addition, nuclear accumulation of E2F4 only
began after 4 hours [9]. This suggests that ERK-dependent
E2F4 phosphorylation may represent an initiating event
for nuclear translocation and that other mechanisms are
also likely implicated. A possible mechanism could be the
heterodimerization of E2F4 with its transcriptional partner
DP-2, reported to promote E2F4 nuclear localization and
activation [26]. One might speculate that E2F4 phosphor-
ylation could promote its association with DP-2 and sub-
sequently, its nuclear re-localization. To our knowledge,
few studies have demonstrated phosphorylation of E2F4
[27-30], and none have linked phosphorylation to the
stimulation of E2F4 function or transcriptional activity.
We show herein that ERK kinases can efficiently and dir-
ectly phosphorylate E2F4 protein in vitro, thus identifying
E2F4 as a novel target of ERK kinases, adding to the list
of ERK substrates implicated in cell proliferation control
[31]. Our analysis of putative ERK1/2 phosphorylation
sequences revealed that S244 and S384 were both im-
plicated in the transcriptional activity of E2F4 and in its
nuclear localization. Nevertheless, more studies are needed
to clearly elucidate the molecular mechanisms of E2F4
activity and localization by phosphorylation.
A novel and intriguing finding of this study is that
stimulation with EGF was not sufficient to induce G1/S
phase transition of human non immortalized intestinal
epithelial cells. These results contrast with those ob-
served in rodent immortalized intestinal epithelial cell
lines in which EGF induced DNA replication and prolif-
eration [15]. Furthermore, many studies have reported
proliferative properties of EGF in organotypic cultures of
human fetal intestinal epithelium, although these studies
did not exclude the contribution of other mesenchymal
and epithelial factors in this effect [32-34]. Many studies
from our laboratory and others have clearly demonstrated
that HIEC are useful and relevant in analyzing the re-
gulation of proliferation of intestinal epithelial crypt cells
in humans [9,10,35,36]. Indeed, the expression of intestinal
epithelial-specific keratins [37], of components specific to
cell junctions [38], cell cycle-related proteins [9,10,39], as
well as typical intestinal cell markers of undifferentiated
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as cells representative of the bottom of the human crypt
[41]. Their epithelial cryptal origin was also confirmed
by their ability to express the 350-kD crypt cell-specific
marker MIM-1/39 [42]. Interestingly, we show herein
that although EGF induced a rapid activation of ERK1/2
similarly to serum and LPA, this action was not sufficient
for S phase entry as visualized by the absence of pRb
hyperphosphorylation, cyclin A protein expression and
E2F4 nuclear translocation. In addition, EGF did not
trigger the degradation of the cell cycle inhibitor p27,
an event necessary to exit the quiescent state and pass
the restriction point [15]. The failure of EGF to induce
G1/S transition in HIEC could be explained by its in-
ability to promote a sustained phosphorylation of Akt.
Indeed, stimulation of Akt by growth factors is known
to be required for G1 progression and S phase entry of
many cell types [43] including intestinal epithelial cells
[16]. Several hypotheses could be suggested to explain
why EGF alone is not sufficient to promote a strong
and sustained Akt activation in HIEC. First, the nature
of EGFR-associated Ras proteins, i.e. H-Ras or K-Ras,
can define the selective activation of ERK or Akt pathway
by EGF [44]. In addition, in colon cancer, activation of
the Rho/Rho-kinase pathway inhibits the capacity of
EGF to promote Akt activation, but not ERK1/2 [45].
Finally, Erk5 was recently shown to be necessary for
sustained PDGF-induced Akt phosphorylation in endo-
thelial cells [46]. Further studies are thus needed to
verify whether these different hypotheses could explain
why EGF alone did not promote a sustained Akt activa-
tion in human intestinal epithelial cells.
Our results also suggest that phosphorylation and in-
hibition of GSK3β play an important role in the nuclear
translocation of E2F4 and the proliferative response of
HIEC. Indeed, serum and LPA, but not EGF, inactivated
GSK3β as visualized by the sustained phosphorylation
on serine 9, probably triggered by Akt or protein kinase
C [22]. Furthermore, when GSK3β was pharmacologic-
ally inhibited, EGF induced pRb hyperphosphorylation,
cyclin D1 expression, p27 degradation and E2F4 nuclear
translocation, four events associated with G1/S phase
transition. It is noteworthy however, that inhibition of
GSK3 only partially rescued the inability of EGF to in-
duce E2F4 nuclear translocation and cell proliferation in
comparison to serum. This could be explained by the
fact that serum contains a number of different additional
factors (including LPA) and hormones in high concen-
trations that may activate various signaling pathways in-
cluding calcium mobilization and PKCs, other signaling
events known to promote proliferation [47]. Nevertheless,
our results suggest that GSK3β, which is tonically active
in quiescent cells, must be phosphorylated and inactivated
to enable cell cycle progression of HIEC. GSK3β im-plication in E2F4 nuclear localization control adds to the
previously described role of GSK3β on E2F1 regulation
by ubiquitination and degradation resulting in a reduced
transcriptional activity [48]. This is also reminiscent of the
observed decreased expression of several other cell cycle
regulated proteins following GSK3 activation, including
c-myc, cyclin D1 and β-catenin [22]. In this regard, ac-
cumulation of these GSK3 substrates has been linked to
increased intestinal proliferation and notably frequently
observed in colorectal cancers [20,23,49,50].
Conclusion
E2F4 protein expression is up-regulated in human colo-
rectal cancers [10,51]. Accordingly, we have previously
shown that E2F4 expression is necessary for both an-
chorage-dependent and independent growth of colo-
rectal cancer cells [10]. Results of the present study
demonstrate that E2F4 protein levels were significantly
enhanced in human adenomas, at an early stage of colo-
rectal cancer. Interestingly, E2F4 expression was mostly
detected in the nucleus and appeared to be phosphory-
lated in adenomas. Of note, the MEK/ERK and GSK3
signaling pathways, shown herein to be implicated in the
regulation of E2F4 phosphorylation and localization, are
known to be involved in colorectal adenoma formation
[23]. Hence, our findings suggest that dysregulated E2F4
nuclear localization may represent one of the instigating
events leading to hyperproliferation and hence of tumor
initiation and promotion in the colon and rectum.
Methods
Material and antibodies
MEK inhibitors U0126 and PD184352 were purchased
from LC Laboratories (Woburn, MA, USA) and GSK3
inhibitor SB216763 was purchased from Sigma-Aldrich
(Oakville, ON, Canada). Antibodies against E2F4 (C-20),
cyclin D1 (C-17), cyclin A (H-432), p27 (C-19), ERK1
(C-16), ERK2 (C-14) and HA-probe (F-7) were all pur-
chased from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA, USA). Phospho-ERK1/2 (Thr202/Tyr204) #9101,
phospho-GSK3β (Ser9) #9336, phospho-glycogen syn-
thase (GS) (Ser641) #3891, phospho-ERK5 (Thr218/
Tyr220) #3371 and phospho-Akt (Ser473) #9271 were
from Cell Signalling Technology (Danvers, MA, USA).
β-actin monoclonal antibody (clone C-4) and recombin-
ant active ERK1 were obtained from Millipore (Billerica,
MA, USA). pRb and Ki67 monoclonal antibodies (clone
35) were purchased from BD BioSciences (Mississauga,
ON, Canada) and phospho-serine antibody (clone 16B4)
from BIOMOL International (#SA-337). Alexa Fluor®
488 goat anti-rabbit and Alexa Fluor® 568 goat anti-mouse
antibodies were from Invitrogen (Carlsbad, CA, USA).
[γ-32P]ATP was obtained from PerkinElmer (Waltham,
QC, Canada). PP1 phosphatase was obtained from New
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materials were from Sigma-Aldrich (Oakville, ON,
Canada) unless stated otherwise.
Expression vectors and construct
The expression vector (pCMV) for HA-DP-2 was obtained
from Dr. J.A. Lees (Department of Biology, Massachusetts
Institute of Technology, Cambridge, USA). The expression
vector (pCDNAneo3) for E2F4 was obtained from Dr.
C. Sardet [52] (Institut de Génétique Moléculaire, Mont-
pellier, France). The full-length human E2F4 cDNA was
subcloned in expression vector pCDNA3.1 in frame with
the HA-tag (at E2F4 N-terminal end). PCR were per-
formed to insert the HA tag in the E2F4 sequence using
oligonucleotides containing the HA-tag and a KOZAK
sequence: 5′ – A GAC TAG GAT CC C ACC ATG TAT
GAT GTT CCT GAT TAT GCT AGC CTC CCG GCG
GAG GCC GGG CCA CAG GCG CCG – 3′ and 5′–
TCT GTA CTC GAG TCA GAG GTT GAG AAC AGG
CAC ATC AAA GAG GTC – 3′. PCR products were next
ligated in BamHI/EcoRI-digested pCDNA3.1 vector. The
E2F4 mutants T224A and T248A were generated by site-
directed mutagenesis using the following oligonucleotides,
respectively: 5′-CCA TCT GCT GTT TCG GCG CCT
CCA CCT CTG CCC AAG- 3′ and 5′-CTT GGG CAG
AGG TGG AGG CGC CGA AAC AGC AGA TGG- 3′;
5′-AAT AGT CCT CAG CTA GCG CCC ACT GCT
GTC CCT- 3′ and 5′- AGG GAC AGC AGT GGG CGC
TAG CTG AGG ACT ATT- 3′. PCR products were next
digested and ligated in BamHI/EcoRI-digested pCDNA3.1
vector. E2F4 mutants T14A, S202A, S218A, S244A, S384A
were generated by Genscript (Piscataway, NJ, USA). E2F4
mutants S244E and S384A were generated by site-directed
mutagenesis using the following oligonucleotides, respect-
ively: 5′ –TCACGTCCAAATGAACCTCAGCTCACT –
3′ and 5′ – AGTGAGCTGAGGTTCATTTGGACGTG
A – 3′; 5′ – TGCCCCTCTGCTTCGTCTTGAACCAC –
3′ and5′ –GTGGTTCAAGACGAAGCAGAGGGGCA–3′.
Cell culture
Non-Immortalized Human Intestinal Epithelial Cells
(HIEC) were isolated by Perreault and Beaulieu [37] from
normal human fetal intestinal epithelium at mid-gestation.
Cells were cultured in Opti-MEM (Invitrogen, Burlington,
ON, Canada) supplemented with 2 mM glutamine (In-
vitrogen), 5% Fetal Bovine Serum (FBS), 10 mM HEPES,
0.5 IU/ml penicillin, 50 μg/ml streptomycin (all obtained
from Wisent, St-Bruno, Canada) and 0.2 IU/ml insulin
(Connaught Novo Laboratories, Willowdale, ON, Canada).
These cells express typical features of the lower adult crypt
region [37,39,40] and are unable to differentiate. The life
span of these normal non immortalized cells is limited to
22–25 passages. Human Embryonic Kidney 293T cells
(ATCC, Manassas, VA, USA) were cultured in Dulbecco′sModified Eagle’s Medium (DMEM; Invitrogen) containing
10% FBS supplemented with 2 mM glutamine, 10 mM
HEPES, 0.5 IU/ml penicillin and 50 μg/ml streptomycin.
HIEC synchronization experiments
HIEC (p18-p21) were grown to a density of 70-80% and
were serum-deprived for 36 h in DMEM after two
washes with Phosphate Buffered Saline (PBS) and two
washes with DMEM medium. FACS analysis confirmed
that 99% of cells were quiescent and in G0 (unpublished
data). Cells were then stimulated with 5% FBS, 100 ng/
ml EGF or 10 μM LPA for 30 min or 24 h with or with-
out a 10 min pre-treatment with DMSO, MEK inhibitors
U0126 (20 μM) or PD184352 (5 μM) or GSK3 inhibitor
SB216763 (20 μM).
Protein extraction and immunoblotting
Cells were washed twice with ice-cold PBS then lysed in
Triton lysis buffer (1% Triton X-100, 50 mM Tris–HCl
pH 7.5, 100 mM NaCl, 5 mM EDTA, 5% glycerol, 40
mM β-glycerophosphate, 50 mM NaF, 200 μM ortho-
vanadate, 5% pepstatin, 5% aprotinin, 5% leupeptin and
5% phenylmethylsulfonyl fluoride (PMSF)) for 30 min
under light agitation. Lysates were then cleared by cen-
trifugation (15 000 g, 10 min) and 4X Laemmli buffer
(2.3% SDS, 10% glycerol, 0.005% bromophenol blue and
5% β-mercaptoethanol) was added to supernatants for
gel analysis. Whole cell extracts were separated on 7.5%
(for E2F4 shift-up) or 10% SDS-PAGE gels and then
electro-transferred onto polyvinylidene fluoride (PVDF)
membranes (Perkin Elmer). Membranes were blocked
for 1 h at 20°C using 0.05% Tween/PBS containing 5%
non-fat dry milk then incubated overnight in primary
antibodies diluted in blocking solution. Membranes were
next incubated with horseradish peroxidase-conjugated
goat anti-mouse or anti-rabbit IgG (GE Healthcare, Baie
d’Urfé, QC, Canada) in blocking solution for 1 h. The
blots were visualized using homemade ECL (Tris–HCl
100 mM pH8.5, 1.25 mM luminol, 225 μM coumaric acid
and 2.9 mM H2O2). Protein concentrations were mea-
sured using BCA procedure (ThermoScientific, Waltham,
MA, USA) as described by the manufacturer with bovine
serum albumin (BSA) as standard.
Immunofluorescence
HIEC were grown on glass coverslips to 70-80% con-
fluency. Cells on coverslips were rapidly rinsed with PBS
and then fixed with 3% paraformaldehyde/PBS for 20
min. Cells were permeabilized with 0.1% Triton X-
100/PBS for 10 min and blocked with 2% BSA/PBS for
20 min. Cells were incubated for 2 h with primary anti-
bodies diluted in blocking solution then immunostained
with anti-rabbit AlexaFluor 488 and anti-mouse Alexa-
Fluor 568 conjugated secondary antibodies. For each
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included. Additional controls were performed to ensure
the absence of cross-reactivity between the wavelengths.
Cells were incubated with Ki67 primary antibody after
which AlexaFluor 568-coupled secondary antibody was
added and fluorescence observed at the designated wave-
lengths used for E2F4 observation (AlexaFluor 488).
PP1 phosphatase assay
HIEC were serum-starved for 36 h then stimulated for
30 min with 5% FBS. Cells were lysed in Triton lysis
buffer without phosphatase inhibitors. Cleared lysates
were incubated with anti-E2F4 antibody (3 h, 4°C) after
which protein A Sepharose CL-4B beads (GE Healthcare)
was added for an additional hour. Immunocomplexes
were washed four times with Triton lysis buffer without
phosphatase inhibitors and twice with phosphatase assay
buffer provided by the manufacturer. Thereafter, 2.5
units of PP1 were added to E2F4 immunocomplexes in
phosphatase buffer and incubated at 30°C for 30 min.
Laemmli’s buffer was added to stop the reaction and
samples were boiled and subsequently loaded on SDS-
PAGE.
Kinase assays
293T cells were transfected with pCDNA3.1 empty vector
or pCDNA3.1 HA-tagged-wild-type E2F4 or mutants
using Lipofectamine 2000 (Invitrogen) according to the
recommended manufacturer protocol. Cells were lysed in
Triton lysis buffer 48 h after transfection. To immunopre-
cipitate E2F4, cleared lysates (1 mg) were pre-incubated
with HA antibody (3 h, 4°C) to which protein A Sepharose
CL-4B beads were added for an additional hour. Immu-
nocomplexes were washed four times with Triton lysis
buffer and twice with kinase assay buffer (25 mM Tris–
HCl pH 7.5, 20 μM EGTA, 10 mM β-glycerophosphate, 1
mM orthovanadate, 400 μM DTT, 30 mM MgCl2 and 30
mM BSA). [γ-32P]ATP (3 μCi/assay) was added and the
reaction initiated by the addition of recombinant active
ERK1 (5 ng) and incubation at 30°C. After 5 min, reactions
were stopped with Laemmli’s buffer. Samples were boiled
and radiolabeled E2F4 was separated from antibodies on
SDS-PAGE gels. Results were visualized by autoradiog-
raphy. After radiography, gels were transferred onto PVDF
membranes and immunoblotted with HA antibody.
Luciferase assays
293T cells were seeded in 6-well plates and co-transfected
by lipofection (Lipofectamine 2000, Invitrogen) with 0.1
μg of thymidine kinase-luciferase reporter, 0.25 μg of
the relevant expression vector (pcDNAneo 3) contain-
ing wild-type E2F4 or mutants and 0.25 μg of the rele-
vant expression vector containing DP-2. The pRL-SV40
Renilla luciferase reporter vector was from Promega(Nepean, ON, Canada). Two days after transfection, lu-
ciferase activity was measured as previously described
[9], according to the Promega protocol.Human adenomas
Samples of colorectal adenomas and paired normal tis-
sues (at least 10 cm from the adenoma) were obtained
from patients undergoing surgical resection. Patients did
not receive neoadjuvant therapy. Tissues were obtained
after patient’s written informed consent, according to the
protocol approved by the Institutional Human Subject
Review Board of the Centre Hospitalier Universitaire de
Sherbrooke. All tissues were frozen in liquid nitrogen
within 30 min from resection. Tissues were embedded,
cryosectioned and immunostained, as described previously
[10]. Genomic DNA was extracted from formalin-fixed
paraffin-embedded tissue using a FFPE DNA Isolation
Kit for Cells and Tissues (Qiagen). APC (exon 15), KRAS
(exons 1 and 2) and BRAF (exon15) were amplified by
PCR and the presence of mutations was detected by direct
sequencing (Plateforme de Séquençage et de Génotypage
des Génomes du CRCHUL, QC, Canada). Paired tissues
were lysed in Triton lysis buffer and immunoblotted as
described above.Data presentation
Assays were performed in triplicate. Typical Western blots
shown are representative of three independent experiments.
Representative results of in situ indirect immunofluores-
cence from three independent experiments are shown.Additional files
Additional file 1: Figure S1. Subconfluent HIEC were serum-deprived for
36 h, treated or not (DMSO) during 10 min with the MEK inhibitors U0126
(20 μM) or PD184352 (5 μM) and then stimulated with 100 ng/ml EGF for 30
min. Thereafter, cells were lysed and proteins were analyzed by SDS-PAGE
for Western blot analysis for the expression of phosphorylated ERK5,
phosphorylated AKT, total AKT and β-actin.
Additional file 2: Figure S2. Subconfluent HIEC were serum-deprived
for 36 h, treated or not (DMSO) during 10 min with the MEK inhibitors
U0126 (20 μM) or PD184352 (5 μM) and then stimulated with 10% serum
for 30 min. Thereafter, cells were lysed and proteins were analyzed by
SDS-PAGE for Western blot analysis for the expression of E2F4, ERK2,
phosphorylated ERK2 and β-actin. Representative of three experiments.Competing interests
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